WuXi AppTec is pleased to announce that Mark Cunningham, Ph.D., has accepted the position of Senior Director of Science and Technology.
Dr. Cunningham brings more than 25 years of experience in the biopharmaceutical and contract research organization (CRO) industries supporting the R&D of pharmaceutical, biotech, medical device and combination products.
Dr. Cunningham received his Ph.D. in pharmaceutical sciences from the University of Kentucky. Following post-doctoral training in cardiovascular pharmacology in the lab of Dr. Benedict Lucchesi at the University of Michigan Medical School, Dr. Cunningham began a career in biotechnology as a Senior Scientist in Pharmacology and Toxicology at Centocor and then at Selective Genetics as Group Leader of Pharmacology. He made the transition from biopharmaceutical research to contract research by joining Sierra Biomedical as the Director of Pharmacology and Surgery.
Previously, Dr. Cunningham was the Chief Scientific Officer of Surpass, Inc. and the Scientific Director for Charles River Laboratories Interventional and Surgical Services – Massachusetts Division. During his employment with Charles River, he also directed departments in Pharmacology, Safety Pharmacology and Surgical Models.
Dr. Cunningham’s area of scientific expertise is the physiology, pharmacology and pathobiology of cardiovascular disease and wound healing with specific interests in preclinical models of inflammation, cardiovascular disease and safety pharmacology. In his career, he has published over 50 papers and abstracts, and he has presented at national and international scientific meetings.